Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12634745 | 0.95 | ALDH1A1 (0.52) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL23723317 | 0.95 | ALDH1A1 (0.52) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL12302263 | 0.95 | ALDH1A1 (0.52) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL8546917 | 0.87 | RAB9A (0.50) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL20248642 | 0.85 | CTSK (0.56) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL12634763 | 0.84 | CTSK (0.52) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL12634718 | 0.84 | CTSK (0.52) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL16307617 | 0.84 | POLB (0.53) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL16307618 | 0.81 | CTSK (0.53) | ALDH1A1KMT2AKDM4EMEN1HPGD | |
| SCHEMBL12137390 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KMT2AKDM4EMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162855-A1 | PDD AND BPD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162855-A1 | PDD AND BPD COMPOUNDS | DRD1, DRD2, XDH | ALDH1A1 869/4885KMT2A 2968/4885KDM4E 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.